Evidence map›Paper›PMID 37064854›Full record

ArticleSisli Etfal Hastanesi tip bulteni2023

Middle Ear Adenomatous Neuroendocrine Tumor: A Case Report and Review of Literature.

Ozan Ozdemir, Ayse Pelin Yigider, Ozgur Yigit

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Sisli Etfal Hastanesi tip bulteni, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 3 countries.

Ozan OzdemirDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Health Sciences Türkiye, Istanbul Training and Research Hospital, Istanbul, Türkiye.
Ayse Pelin YigiderDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Health Sciences Türkiye, Istanbul Training and Research Hospital, Istanbul, Türkiye.
Ozgur YigitDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Health Sciences Türkiye, Istanbul Training and Research Hospital, Istanbul, Türkiye.
University of Health Science · KH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Middle ear adenomatous neuroendocrine tumor (MEANT) is a rare entity and accounts for approximately 2% of all middle ear tumors. Histologically, the presence of neuroendocrine and glandular structures has led to the use of a wide variety of terminologies such as adenoma, carcinoid tumor, and neuroendocrine tumor. The patients usually have nonspecific symptoms such as unilateral hearing loss, auditory fullness, tinnitus, and otalgia. There is no specific radiological finding. A definitive diagnosis is based on complete removal of the tumor and combined histopathology and immunohistochemical examination. In this case-report, we describe a patient with MEANT who complained of hearing loss and auditory fullness in her left ear. Otomicroscopy revealed a mass of polypoid tissue filling the left external auditory canal. In the pure tone audiometry test, the pure-tone average was reported as L45/5 R10/0, and the tympanogram was type B on the left ear. In temporal bone computed tomography, the soft-tissue mass located in the middle ear was found to extend to the antrum and the external auditory canal. Biopsy taken under local anesthesia from the visible mass in the external auditory canal was reported as MEANT and the diagnosis was confirmed by histopathology and immunochemistry after surgery.

Indexed as

AdenomaCarcinoid tumorMiddle earNeuroendocrine tumor

Identifiers

PMID37064854
PMCPMC10098404
OpenAlexW4225773240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.